Cui Yang1, Julia Brecht1, Christel Weiß2, Christoph Reissfelder1, Mirko Otto1, Jane N Buchwald3, Georgi Vassilev4. 1. Department of Surgery, University Medicine Mannheim, Medical Faculty Mannheim, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany. 2. Department of Medical Statistics and Biomathematics, Medical Faculty Mannheim, Heidelberg University, 68167, Mannheim, Germany. 3. Division of Scientific Research Writing, Medwrite Medical Communications, Maiden Rock, WI, 54750, USA. 4. Department of Surgery, University Medicine Mannheim, Medical Faculty Mannheim, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany. georgi.vassilev@umm.de.
Abstract
BACKGROUND: Metabolic/bariatric surgery is a highly effective treatment for obesity and metabolic diseases. Serum glucagon, bile acids, and FGF-19 are key effectors of various metabolic processes and may play central roles in bariatric surgical outcomes. It is unclear whether these factors behave similarly after Roux-en-Y gastric bypass (RYGB) vs vertical sleeve gastrectomy (VSG). METHODS: Serum glucagon, bile acids (cholic acid [CA], chenodeoxycholic acid [CDCA], deoxycholic acid [DCA]), and FGF-19 were analyzed in samples of fasting blood collected before bariatric surgery, on postoperative days 2 and 10, and at 3- and 6-month follow-up. RESULTS: From September 2016 to July 2017, patients with obesity underwent RYGB or VSG; 42 patients (RYGB n = 21; VSG n = 21) were included in the analysis. In the RYGB group, glucagon, CA, and CDCA increased continuously after surgery (p = 0.0003, p = 0.0009, p = 0.0001, respectively); after an initial decrease (p = 0.04), DCA increased significantly (p = 0.0386). Serum FGF-19 was unchanged. In the VSG group, glucagon increased on day 2 (p = 0.0080), but decreased over the 6-month study course (p = 0.0025). Primary BAs (CA and CDCA) decreased immediately after surgery (p = 0.0016, p = 0.0091) and then rose (p = 0.0350, p = 0.0350); DCA followed the curve of the primary BAs until it fell off at 6 months (p = 0.0005). VSG group serum FGF-19 trended upward. CONCLUSION: RYGB and VSG involve different surgical techniques and final anatomical configurations. Between postoperative day 2 and 6-month follow-up, RYGB and VSG resulted in divergent patterns of change in serum glucagon, bile acids, and FGF-19.
BACKGROUND: Metabolic/bariatric surgery is a highly effective treatment for obesity and metabolic diseases. Serum glucagon, bile acids, and FGF-19 are key effectors of various metabolic processes and may play central roles in bariatric surgical outcomes. It is unclear whether these factors behave similarly after Roux-en-Y gastric bypass (RYGB) vs vertical sleeve gastrectomy (VSG). METHODS: Serum glucagon, bile acids (cholic acid [CA], chenodeoxycholic acid [CDCA], deoxycholic acid [DCA]), and FGF-19 were analyzed in samples of fasting blood collected before bariatric surgery, on postoperative days 2 and 10, and at 3- and 6-month follow-up. RESULTS: From September 2016 to July 2017, patients with obesity underwent RYGB or VSG; 42 patients (RYGB n = 21; VSG n = 21) were included in the analysis. In the RYGB group, glucagon, CA, and CDCA increased continuously after surgery (p = 0.0003, p = 0.0009, p = 0.0001, respectively); after an initial decrease (p = 0.04), DCA increased significantly (p = 0.0386). Serum FGF-19 was unchanged. In the VSG group, glucagon increased on day 2 (p = 0.0080), but decreased over the 6-month study course (p = 0.0025). Primary BAs (CA and CDCA) decreased immediately after surgery (p = 0.0016, p = 0.0091) and then rose (p = 0.0350, p = 0.0350); DCA followed the curve of the primary BAs until it fell off at 6 months (p = 0.0005). VSG group serum FGF-19 trended upward. CONCLUSION: RYGB and VSG involve different surgical techniques and final anatomical configurations. Between postoperative day 2 and 6-month follow-up, RYGB and VSG resulted in divergent patterns of change in serum glucagon, bile acids, and FGF-19.
Authors: Jonathan Q Purnell; Geoffrey S Johnson; Abdus S Wahed; Chiara Dalla Man; Francesca Piccinini; Claudio Cobelli; Ronald L Prigeon; Bret H Goodpaster; David E Kelley; Myrlene A Staten; Karen E Foster-Schubert; David E Cummings; David R Flum; Anita P Courcoulas; Peter J Havel; Bruce M Wolfe Journal: Diabetologia Date: 2018-02-10 Impact factor: 10.122
Authors: Bethany P Cummings; Ahmed Bettaieb; James L Graham; Kimber L Stanhope; Mark Kowala; Fawaz G Haj; Michael L Chouinard; Peter J Havel Journal: Endocrinology Date: 2012-06-19 Impact factor: 4.736
Authors: Mia Demant; Jonatan I Bagger; Malte P Suppli; Asger Lund; Mette Gyldenløve; Katrine B Hansen; Kristine J Hare; Mikkel Christensen; David P Sonne; Jens J Holst; Tina Vilsbøll; Filip K Knop Journal: Metab Syndr Relat Disord Date: 2018-10-16 Impact factor: 1.894
Authors: Dimitri J Pournaras; Clare Glicksman; Royce P Vincent; Shophia Kuganolipava; Jamie Alaghband-Zadeh; David Mahon; Jan H R Bekker; Mohammad A Ghatei; Stephen R Bloom; Julian R F Walters; Richard Welbourn; Carel W le Roux Journal: Endocrinology Date: 2012-06-06 Impact factor: 4.736
Authors: S H Jacobsen; S C Olesen; C Dirksen; N B Jørgensen; K N Bojsen-Møller; U Kielgast; D Worm; T Almdal; L S Naver; L E Hvolris; J F Rehfeld; B S Wulff; T R Clausen; D L Hansen; J J Holst; S Madsbad Journal: Obes Surg Date: 2012-07 Impact factor: 4.129
Authors: James M Isbell; Robyn A Tamboli; Erik N Hansen; Jabbar Saliba; Julia P Dunn; Sharon E Phillips; Pamela A Marks-Shulman; Naji N Abumrad Journal: Diabetes Care Date: 2010-04-05 Impact factor: 19.112